Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
https://doi.org/10.14412/1995-4484-2011-862
Abstract
The paper analyzes the efficiency and tolerability of a combination of rituximab (RTM) and leflunomide (LEF) for the treatment of rheumatoid arthritis (RA) versus the conventional combination of RTM and methotrexate (MT). The results of 24-week therapy were assessed in the RA patients included into the Russian Biological Therapy Register. A good effect of therapy was achieved in 31.8% of the patients who had received RTM+LEF (p = 0.1). The development of clinical remissions in RA was observed at a practically equal frequency of 13.6 and 11.7%, respectively. The doses of glucocorticoids and nonsteroidal anti-inflammatory drugs used in concurrent anti-inflammatory therapy could be substantially reduced in both groups. In both groups, the rate of side effects was very equal: 21.7% for the RTM+LEF group and 25.7% for the RTM+MT group. Thus, the combination therapy of RTM and LEF in real clinical practice is not considerably different from the most commonly used combination of RMT and MT in efficiency and tolerability and may be successfully used if there are any contraindications to the use of MT.
About the Authors
Evgeniy L'vovich NasonovG V Lukina
Ya A Sigidin
Evgeny Lvovich Nasonov
G V Lukina
Ya A Sigidin
References
1. <div><p>Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 290-331.</p><p>Klareskog L., Cartina A.I., Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-72.</p><p>Smolen J.S., Aletaha D., Bijsma J.W.J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.</p><p>Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.</p><p>Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин. мед. 2005; 6: 8-12.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер. арх. 2007; 5: 5-8.</p><p>Решетняк Д.В., Насонов Е.Л. Новые направления лечения ревматоидного артрита: механизмы действия и клиническая эффективность лефлуномида. Науч.- практич. ревматол. 2001; 5: 39-45.</p><p>Gaujoux-Viala C., Smolen J.S., Landewe R. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010 (on-line).</p><p>Чичасова Н.В., Насонов Е.Л. Лефлуномид в лечении ревматических заболеваний. М.: МегаПро, 2010; 110 с.</p><p>Jones P.B.B., White D.H.N. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol Res Rev 2010; 2: 53-71.</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumat- ic drugs in rheumatoid arthritis. Arthr Rheum 2008; 59: 762-84.</p><p>Насонов Е.Л. Перспективы комбинированной терапии ревматоидного артрита - лефлуномид и инфликсимаб. Рус. мед. журн. 2008; 16(10): 633-7.</p><p>Strangfeld A., Hierse F., Kekow J. et al. Comparative effectiveness of tumor necrosis factor a inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68: 1856-62.</p><p>Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите: 2010. Науч.-практич. ревматол. 2010; 4(Прил. 1) : 10-40.</p><p>Vital Е., Dass S., Rawstron A.C., Emery P. Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl. II) : 90.</p><p>Henes J., Schedel J., Kanz L. et al. Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis. Rheumatol Int 2010; 30: 709-12.</p><p>Wendler J., Soerensen H.,Tony H. et al. Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) and leflunomide (LEF) in the German RTX treatment of active rheumatoid arthritis (RA) in daily practice trial. Ann Rheum Dis 2009; 68(Suppl. 3): 76.</p><p>Narvaez J., Torne C.D., Ruiz J.M. et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Arthr Rheum 2010; 62(Suppl.): S748 [1796].</p><p>Gabay C., Chatzidionysiou K., Nasonov E. et al. Effectiveness of different DMARD co-therapy in Rituximab-treated rheumatoid arthritis (RA) patients - results of a one-year follow up study from the CERERRA collaboration. Ann Rheum Dis 2010; 69(Suppl. 3): 68.</p></div><br />
Review
For citations:
Nasonov E.L., Lukina G.V., Sigidin Ya.A., Nasonov E.L., Lukina G.V., Sigidin Ya.A. Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry). Rheumatology Science and Practice. 2011;49(1):16-20. (In Russ.) https://doi.org/10.14412/1995-4484-2011-862
Views:
1220
Email this article 